TB-500 vs Dermorphin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
Also: Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, Frog juice
Dermorphin is a seven-amino-acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first found in the skin of South American Phyllomedusa frogs. It is a strong, highly selective mu-opioid agonist, the same receptor morphine and fentanyl hit, and in mouse brain-injection studies it was hundreds of times more potent than morphine. It is not approved anywhere for human use. Its main claim to fame is doping: it was caught in dozens of American racehorses in 2012, where it was nicknamed 'frog juice'. This is an opioid, and it should be treated like one.
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
Detailed Comparison
| Attribute | TB-500 | Dermorphin |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin beta-4 works by grabbing onto G-actin, the building-block form of actin, and acting as the main reservoir cells use to remodel their cytoskeleton. That control over actin lets cells migrate into wounds, which is the proposed basis for faster tissue repair. The active heptapeptide sequence LKKTETQ is the piece that does the actin binding, and TB-500 is built around it. Beyond cell movement, thymosin beta-4 has shown anti-inflammatory effects and pro-angiogenic activity in lab models. Keep in mind that injecting a short synthetic fragment is not guaranteed to reproduce everything the full protein does, so the mechanism story is borrowed largely from research on the parent molecule. | Dermorphin binds the mu-opioid receptor with very high affinity and selectivity. In rat brain binding work it had a Ki of 0.7 nM at mu receptors versus 62 nM at delta and over 5,000 nM at kappa receptors, a selectivity on par with the reference lab mu-agonist DAMGO. It is unusual for a natural peptide because its second amino acid is a D-alanine, which protects it from the enzymes that normally chew up opioid peptides within seconds. Mu activation blocks pain signaling in the spinal cord and brain, and it also drives the classic opioid problems: euphoria, sedation, slowed breathing, constipation, tolerance and dependence. There is no special 'safe' mechanism here. Claims that it is less addictive than morphine are mostly marketing and horse-racing talk, not proven in people. |
| Common Dosing | 2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) 2x weekly for 4-6 weeks, then 1x weekly | No safe human dose established Not established |
| Administration | Subcutaneous or intramuscular injection | Intravenous infusion (human study); intravenous or intramuscular (horse study) |
| Typical Duration | 4-6 weeks loading, then maintenance | Single administrations in research settings |
| Best Time to Take | Morning or evening | Not applicable |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The strongest evidence is preclinical and is mostly about full-length thymosin beta-4, not the TB-500 fragment. Animal studies consistently show accelerated wound healing, reduced scarring, and improved recovery in tendon, skin, and cardiac injury models. On the human side, the biotech company RegeneRx ran the molecule (as RGN-259 eye drops and RGN-352 injection) through actual clinical trials: a placebo-controlled Phase 3 study of RGN-259 in neurotrophic keratopathy reported corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo, and an injectable cardiac program reached Phase 2 before a manufacturing hold. But those programs used full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment sold for research. For the fragment specifically, there are no completed, published human efficacy trials for muscle or tendon repair, and a recently listed cardiovascular biomarker study is early-stage. So: real animal data, real human data for the parent protein, and a near-total gap for TB-500 as sold. | Most of the science is animal pharmacology and drug-testing chemistry. A 1990 rat-brain study confirmed dermorphin as a near-specific mu 'super-agonist' and found that, injected into the brains of mice, it was up to 670 times more potent than morphine as a painkiller, with higher doses causing catalepsy. The human data are tiny: a 1986 Brain Research study gave an intravenous infusion of 0.16 mg/kg to healthy volunteers and found a marked, long-lasting rise in the threshold of a spinal pain reflex; naloxone only reversed about half the effect. No modern clinical trials exist. In horses, a 2015 pharmacokinetic study (about 9 mcg/kg IV or IM) found an elimination half-life under an hour, excitation with a raised heart rate after IV dosing, and detection in urine for 48 to 72 hours. The doping story is the reason most people have heard of it: around 30 positive tests turned up in Southern US racing in 2012, including 11 horses tied to nine trainers in Louisiana, which led to suspensions of up to 10 years, and racing labs in Australia, the US and Hong Kong have since built sensitive tests for dermorphin and its synthetic analogs. A 2017 federal indictment charged a Louisiana veterinarian with supplying it to trainers. |
Frequently Asked Questions: TB-500 vs Dermorphin
What is the difference between TB-500 and Dermorphin?
TB-500 is a healing peptide that tb-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. most tb-500 products reproduce the short lkktetq sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. here is the honest part: there are essentially no completed human trials of the tb-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing. Dermorphin is a healing peptide that dermorphin is a seven-amino-acid opioid peptide (tyr-d-ala-phe-gly-tyr-pro-ser-nh2) first found in the skin of south american phyllomedusa frogs. it is a strong, highly selective mu-opioid agonist, the same receptor morphine and fentanyl hit, and in mouse brain-injection studies it was hundreds of times more potent than morphine. it is not approved anywhere for human use. its main claim to fame is doping: it was caught in dozens of american racehorses in 2012, where it was nicknamed 'frog juice'. this is an opioid, and it should be treated like one. The main differences lie in their mechanisms of action and clinical applications.
Which is better, TB-500 or Dermorphin?
Neither is universally "better" - the choice depends on your specific goals. TB-500 is typically used for healing purposes, while Dermorphin is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can TB-500 and Dermorphin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using TB-500 and Dermorphin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.